182 related articles for article (PubMed ID: 32068910)
1. The impact of drug interactions on adverse effects of oral oxycodone in male geriatric patients.
Kim JH; Kim JY; Lee N; Yee J; Gwak HS
J Clin Pharm Ther; 2020 Oct; 45(5):976-982. PubMed ID: 32068910
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of opioid-induced adverse reactions in elderly male outpatients of Korea Veterans Hospital.
Kim JY; Kim JH; Yee J; Song SJ; Gwak HS
BMC Geriatr; 2018 Nov; 18(1):293. PubMed ID: 30486785
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
4. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
[TBL] [Abstract][Full Text] [Related]
5. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
[TBL] [Abstract][Full Text] [Related]
6. Importance of cytochrome 3A4 and 2D6-mediated drug-drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study.
Decaix T; Gautier S; Royer L; Laprévote O; Tritz T; Siguret V; Teillet L; Sellier C; Pépin M
Aging Clin Exp Res; 2023 Nov; 35(11):2471-2481. PubMed ID: 37861957
[TBL] [Abstract][Full Text] [Related]
7. Observations of urinary oxycodone and metabolite distributions in pain patients.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
[TBL] [Abstract][Full Text] [Related]
8. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
[TBL] [Abstract][Full Text] [Related]
9. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
[TBL] [Abstract][Full Text] [Related]
10. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.
Andreassen TN; Eftedal I; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2012 Jan; 68(1):55-64. PubMed ID: 21735164
[TBL] [Abstract][Full Text] [Related]
11. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Laine K; Olkkola KT
Clin Drug Investig; 2011; 31(3):143-53. PubMed ID: 21142269
[TBL] [Abstract][Full Text] [Related]
12. A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability.
Makihara K; Yamamoto Y; Miyazaki M; Taguchi M; Sato J; Takase H; Uezono Y
J Pain Palliat Care Pharmacother; 2024 Mar; 38(1):3-12. PubMed ID: 38227839
[TBL] [Abstract][Full Text] [Related]
13. Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers.
Coyle DT; Woodworth TS; Moeny D; Staffa J; Meyer T; Woods C; Welch EC; Haynes K; Toh S; Maro JC
J Manag Care Spec Pharm; 2020 May; 26(5):668-672. PubMed ID: 32347183
[TBL] [Abstract][Full Text] [Related]
14. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.
Grönlund J; Saari TI; Hagelberg N; Neuvonen PJ; Olkkola KT; Laine K
Antimicrob Agents Chemother; 2011 Mar; 55(3):1063-7. PubMed ID: 21173180
[TBL] [Abstract][Full Text] [Related]
15. Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study.
Yang J; Sun YZ; Li QF; Fu Z; Guan YY; Song C; Zheng L
BMC Pharmacol Toxicol; 2023 Nov; 24(1):64. PubMed ID: 37990344
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study.
Möller J; Laflamme L; Söderberg Löfdal K
Basic Clin Pharmacol Toxicol; 2015 Feb; 116(2):134-9. PubMed ID: 24975450
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.
Tulner LR; Frankfort SV; Gijsen GJ; van Campen JP; Koks CH; Beijnen JH
Drugs Aging; 2008; 25(4):343-55. PubMed ID: 18361544
[TBL] [Abstract][Full Text] [Related]
18. How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain?
Richarz U; Jacobs A; Spina E
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):453-62. PubMed ID: 22081534
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
20. Opioid-induced respiratory depression suspected of drug interaction in a prostate cancer patient: a case report.
Hamada H; Suzuki E; Endo M; Mihara Y; Iketani S; Ishida M; Miyasato A; Miyazaki K
Ann Palliat Med; 2024 Mar; 13(2):428-432. PubMed ID: 38584476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
